Canadian Natural Resources Ltd. Stock Rises Thursday, Outperforms Market
Dow Jones2026/08/20 20:31This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Canadian Natural Resources Ltd. CNQ rallied 2.86% to C$70.44 Thursday, in what proved to be an otherwise all-around poor trading session for the Canadian market, with the S&P/TSX Composite Index falling 0.10% to 36,365.42.
Canadian Natural Resources Ltd. closed 0.8% short of its 52-week high of C$70.99, which the company reached on March 30th.
Trading volume of 7.9 M shares remained below its 50-day average volume of 13.6 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 20, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
August 20, 2026 16:31 ET (20:31 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
Crypto prices
More
